These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 25394135)

  • 1. Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study.
    Neukam K; Espinosa N; Merino D; Rivero-Juárez A; Carrero A; Ríos MJ; Ruiz-Morales J; Gómez-Berrocal A; Téllez F; Díaz-Menéndez M; Collado A; Pérez-Camacho I; Delgado-Fernández M; Vera-Méndez F; Pineda JA
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19631. PubMed ID: 25394135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study.
    Neukam K; Espinosa N; Collado A; Delgado-Fernández M; Jiménez-Aguilar P; Rivero-Juárez A; Hontañón-Antoñana V; Gómez-Berrocal A; Ruiz-Morales J; Merino D; Carrero A; Téllez F; Ríos MJ; Hernández-Quero J; de Lagarde-Sebastián M; Pérez-Camacho I; Vera-Méndez F; Macías J; Pineda JA;
    PLoS One; 2016; 11(5):e0155842. PubMed ID: 27195797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114.
    Pérez-Hernández IA; Palacios R; Mayorga M; González-Doménech CM; Castaño M; Rivero A; Del Arco A; Lozano F; Santos J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19795. PubMed ID: 25397539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients.
    Macías J; Neukam K; Mallolas J; López-Cortés LF; Cartón JA; Domingo P; Moreno S; Iribarren JA; Clotet B; Crespo M; de Los Santos I; Ortega E; Knobel H; Jiménez-Expósito MJ; Pineda JA;
    HIV Clin Trials; 2012; 13(2):61-9. PubMed ID: 22510353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort.
    Neukam K; Mira JA; Collado A; Rivero-Juárez A; Monje-Agudo P; Ruiz-Morales J; Ríos MJ; Merino D; Téllez F; Pérez-Camacho I; Gálvez-Contreras MC; Rivero A; Pineda JA;
    PLoS One; 2016; 11(2):e0148104. PubMed ID: 26848975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
    Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
    AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment.
    Sweet D; Song J; Zhong Y; Signorovitch J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19537. PubMed ID: 25394046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre.
    Borghetti A; Mondi A; Piccoli B; Gagliardini R; Lamonica S; Ciccarelli N; D'Avino A; Pallavicini F; Cauda R; De Luca A; Fabbiani M; Di Giambenedetto S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19817. PubMed ID: 25397561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study.
    Gagliardini R; Rossetti B; Bianco C; Rusconi S; Colafigli M; Prinapori R; Francisci D; Fantauzzi A; Orofino G; Vignale F; Di Giambenedetto S; De Luca A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19818. PubMed ID: 25397562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.
    Pinnetti C; Di Giambenedetto S; Maggiolo F; Lorenzini P; Fabbiani M; Tommasi C; Latini A; Ammassari A; Loiacono L; Sterrantino G; Bellagamba R; Boumis E; Antinori A; Zaccarelli M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19812. PubMed ID: 25397556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis.
    Stellbrink HJ; Antinori A; Pozniak A; Flamm J; Bredeek F; Patel K; Garner W; Piontkowsky D
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19793. PubMed ID: 25397537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
    Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
    AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
    Gallien S; Flandre P; Nguyen N; De Castro N; Molina JM; Delaugerre C
    J Med Virol; 2015 Feb; 87(2):187-91. PubMed ID: 25070158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study.
    Podzamczer D; Rozas N; Domingo P; Ocampo A; Van den Eynde E; Deig E; Vergara A; Knobel H; Pasquau J; Antela A; Crespo M; Clotet B; Muñoz J; Fernandez P; Geijo P; de Castro ER; Diz J; Casado A; Torres C
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19814. PubMed ID: 25397558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy.
    Cozzi-Lepri A; Antinori A; Bonora S; Cingolani A; Cassola G; Angarano G; Vullo V; Mussini C; Gori A; Maggiolo F; Castagna A;
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19771. PubMed ID: 25397515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.
    Curtis L; Nichols G; Stainsby C; Lim J; Aylott A; Wynne B; Clark A; Bloch M; Maechler G; Martin-Carpenter L; Raffi F; Min S
    HIV Clin Trials; 2014; 15(5):199-208. PubMed ID: 25350958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19605. PubMed ID: 25394109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis.
    Arribas J; Rizzardini G; Arasteh K; Zurawski C; Dietz C; Pontani D; Garner W; Nguyen T
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19805. PubMed ID: 25397549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.